Table 6 Phase III 1991–2000: Exploration of α-, β- and γ-cyclodextrin derivatives for drug delivery supported by animal studies
From: Chronicle updates in cyclodextrin-based carriers for drug delivery
S. No | Year | CD type/Derivative | Studies involved | System/Model | Reference |
|---|---|---|---|---|---|
1 | 1991 | β-CD, DM-β-CD and HP-β-CD | Absorption and pharmacokinetics study was conducted | In vivo (Rabbit) | Marques et al. (1991) |
2 | 1991 | α-CD, β-CD, γ-CD, DM-β-CD and HP-β-CD | Absorption enhancing effect on intra-nasal insulin with different CDs and derivatives was investigated | In vivo (Rats) | Merkus et al. (1991) |
3 | 1991 | HP-β-CD | Metabolization was quickly improved by using HP-β-CD without the sustained elevations of dihydrotestosterone | In vivo | Stuenkel et al. (1991) |
4 | 1992 | β- CD | Suppressing outcome of β CD on the photo-isomerization of IMC was confirmed by nuclear magnetic resonance, ultraviolet and circular dichroism | − | Hirayama et al. (1992) |
5 | 1993 | β- CD | β- CD improves the ocular bioavailability of pilocarpine | In vivo | Freedman et al. (1993) |
6 | 1994 | β- and γ-CD derivatives | In presence of L-α-lysophosphatidylcholine and glycodeoxycholate enhancers the nasal absorption of insulin were studied | In vivo | Gill et al. (1994) |